 |
|
|
| |
FINAL RESULTS: Randomized, Double-blind, Placebo-controlled Safety, Anti-viral, Proof of Concept Study of Miravirsen, an Oligonucleotide Targeting miR-122, in Treatment-Naïve Patients with Genotype 1 Chronic HCV Infection
|
| |
| |
Reported by Jules Levin
EASL 2012
H. W. Reesink1; H. L. A. Janssen2; S. Zeuzem3; E. Lawitz4; M. Rodriguez-Torres5; K. Patel6; A. Chen7; C. Davis7; B. King7; A. A. Levin7; M. R. Hodges7
1. Academic Medical Center, Amsterdam, The Netherlands
2. Erasmus MC University Hospital, Rotterdam, The Netherlands
3. J.W. Goethe University Hospital, Frankfurt, Germany
4. Alamo Medical Research, San Antonio, TX, United States
5. Fundacion de Investigacion de Diego, San Juan, Puerto Rico
6. Duke University, Durham, NC
7. Santaris Pharma A/S, San Diego, CA, United States
|
| |
|
|
|
|
|
